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During formation of the neuromuscular junction (NMJ), agrin secreted by motor axons signals the embryonic muscle cells to organize a
postsynaptic apparatus including a dense aggregate of acetylcholine receptors (AChRs). Agrin signaling at the embryonic NMJ requires the
activity of nitric oxide synthase (NOS). Common downstream effectors of NOS are guanylate cyclase (GC), which synthesizes cyclic GMP, and
cyclic GMP-dependent protein kinase (PKG). Here we show that GC and PKG are important for agrin signaling at the embryonic NMJ of the frog,
Xenopus laevis. Inhibitors of both GC and PKG reduced endogenous AChR aggregation in embryonic muscles by 50–85%, and blocked agrin-
induced AChR aggregation in cultured embryonic muscle cells. A cyclic GMP analog, 8-bromo-cyclic GMP, increased endogenous AChR
aggregation in embryonic muscles to 3- to 4-fold control levels. Overexpression of either GC or PKG in embryos increased AChR aggregate area
by 60–170%, whereas expression of a dominant negative form of GC inhibited endogenous aggregation by 50%. These results indicate that agrin
signaling in embryonic muscle cells requires the activity of GC and PKG as well as NOS.
© 2007 Elsevier Inc. All rights reserved.Keywords: Neuromuscular junction; Synapse formation; Agrin; Muscle cells; Acetylcholine receptors; Nitric oxide; Cyclic GMP; Guanylate cyclase; Cyclic GMP-
dependent protein kinase; Xenopus embryosIntroduction
Formation of the neuromuscular junction (NMJ), a well-
studied synapse, is a complex process which occurs over a
period of days to weeks in embryos of different species (Sanes
and Lichtman, 1999b). Assembly of the postsynaptic appara-
tus, and, indirectly, the nerve terminal, is directed by agrin
released by motor axons (Gautam et al., 1996; Cohen et al.,
1997; Jones et al., 1997). Postsynaptic proteins, including⁎ Corresponding author. Fax: +1 757 446 5719.
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doi:10.1016/j.ydbio.2007.04.021acetylcholine receptors (AChRs), are directed by agrin to
aggregate into stable structures anchored to the actin
cytoskeleton (Dai et al., 2000; reviewed in Godfrey and
Schwarte, 2003). Agrin acts in muscle cells through a
membrane tyrosine kinase, MuSK, a component of the agrin
receptor (DeChiara et al., 1996; Glass et al., 1996, 1997).
However, signaling steps downstream of MuSK activation
leading to aggregation of postsynaptic AChRs and other
proteins are not well defined. Understanding the molecular
mechanisms involved in assembly of the neuromuscular
junction will provide a basis for comparison with signaling
events in formation and plasticity of synapses in the central
nervous system (CNS), and may also suggest therapeutic
approaches for neuromuscular diseases.
Nitric oxide synthase (NOS), an enzyme that synthesizes the
free radical gas nitric oxide (NO), is concentrated postsynapti-
cally at the NMJ (Chao et al., 1997; Yang et al., 1997), and NO
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(Wang et al., 1995). NOS is also localized postsynaptically at
some CNS synapses, and NO has been implicated as a
retrograde signaling molecule in long-term potentiation (Haw-
kins et al., 1998). NOS activity is required for agrin signaling of
AChR aggregation in chicken skeletal muscle cells (Jones and
Werle, 2000) and in Xenopus embryo muscles (Godfrey and
Schwarte, 2003). Overexpression of NOS in Xenopus embryos
greatly increases AChR aggregate area at embryonic NMJs,
whereas NOS inhibitors block endogenous AChR aggregation
50–90% and completely block agrin-induced aggregation
in cultured embryonic muscle cells (Schwarte and Godfrey,
2004).
Common downstream effectors of NO signaling in cells
include guanylate cyclase (GC), the enzyme that synthesizes
cyclic GMP (cGMP), and cyclic GMP-dependent protein kinase
(PKG; Hofmann et al., 2000). Agrin-induced aggregation of
AChRs into large, dense clusters in the membrane of cultured
chicken muscle cells requires activity of both GC and PKG
(Jones and Werle, 2004). Here we asked whether GC and PKG
activities are also necessary for synaptic aggregation of AChRs
during formation of the embryonic NMJ. Inhibitors of both GC
and PKG reduced AChR aggregation at the NMJ, and blocked
agrin-induced increases in AChR aggregation in cultured
embryonic muscle cells. Conversely, overexpression of either
GC or PKG increased AChR aggregate area at the NMJ, as did a
cyclic GMP analog, but a dominant negative form of GC
inhibited synaptic aggregation. These data strongly suggest that
GC and PKG are involved in agrin signaling of postsynaptic
differentiation at the embryonic NMJ and in cultured muscle
cells.
Materials and methods
cDNAs; RNA synthesis
The cDNA encoding green fluorescent protein (GFP; S65T mutant) was
obtained from Dr. Richard Dorsky (University of Utah). The cDNAs coding
for rat soluble GC subunits α and β (Chinkers et al., 1989; Yuen et al.,
1994) were a gift of Dr. David Garbers (University of Texas Southwestern
Medical School), and a dominant negative GC α1 construct (D529A mutant;
Yuen et al., 1994) was obtained from Dr. Peter Yuen (National Institutes of
Health). The cDNAs encoding bovine cGMP-dependent protein kinase Iα
(PKG; Wernet et al., 1989) and a constitutively active form of human PKGIα
(PKG-GFP fusion protein; Browning et al., 2001) were from Dr. Bonnie
Firestein (Rutgers University) and Dr. Darren Browning (Medical College of
Georgia), respectively. Protein coding sequences of all cDNAs were
amplified by PCR. Sense primers contained the SP6 RNA polymerase
promoter and the 5′ untranslated sequence from Xenopus beta globin found
in the pCS2 vector (Godfrey et al., 2000; Rupp et al., 1994). RNA was
synthesized using SP6 polymerase and the mMessage Machine kit (Ambion;
Godfrey et al., 1999).
RNA injection
Embryos of Xenopus laevis were obtained by in vitro fertilization (Moon
and Christian, 1989) and injected with synthetic RNAs at the one-cell stage
using a Nanoject II injector (Drummond) fitted with glass micropipets (20 μm
diameter tip). Embryos were injected (Moon and Christian, 1989) with 4.6–
9.2 nl nuclease-free water containing GFP RNA (1–2 ng) alone or combined
with RNAs encoding GC or PKG (3–12 ng).Screening embryos and labeling acetylcholine receptors
Following injection of RNAs, embryos were transferred into 0.1× modified
Barth's solution (MBS; Gurdon and Wickens, 1983) and allowed to develop to
stage 31 (Nieuwkoop and Faber, 1994), then screened for GFP fluorescence.
Embryos were fixed and AChRs were labeled with 1.5 μg/ml Alexa 594-α-
bungarotoxin (Invitrogen) as described (Schwarte and Godfrey, 2004).
Confocal microscopy and image analysis
AChR aggregates were imaged using a confocal microscope (Zeiss LSM
510). Six stacks of images were acquired from three to six embryos for each
condition, two stacks of 4 optical sections (at 1 μm intervals) from each of
myotomes 4, 5, and 6 (Godfrey et al., 1999). The images were taken through a
40 × objective with a 2.5-fold optical zoom (total magnification 100×). Optical
sections were imaged to show innervated (medial) portions of the muscles in
which AChR aggregates formed a continuous line, and were centered along the
intermyotomal septa where NMJs form. Since muscle cells at this stage were
about 10 μm in diameter, each 4 μm stack imaged primarily one set of cells. The
area of AChR aggregates in a montage of all 4 images in each stack was
measured with Metamorph image analysis software (Universal Imaging Corp.).
Threshold was set to mark aggregates in each series of images, and aggregate
area was converted to a percentage of the total area of the montaged images.
Statistics were calculated as described (Godfrey et al., 1999).
Treatment of embryos with GC and PKG inhibitors and a cGMP
analog
Embryos were exposed to the GC inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha]
quinoxalin-1-one (ODQ), the PKG inhibitor Rp-8-pCPT-cGMPS (Rp-8), or 8-
bromo-cyclic GMP (8-Br-cGMP) from26 h of development (stage 24) to stage 31,
a period of 18–20 h at 16–18 °C. Reagents (Biomol or EMD Biosciences) were
dissolved in 1×MBS. In some experiments, penetration of inhibitors into muscles
was facilitated by removing the skin overlying the trunkmyotomes and dissolving
inhibitors in cell culture medium. AChR aggregates were labeled and their area
was quantified as described above. Skin was removed frommyotomes of embryos
treated with Rp-8 in some experiments with 8-Br-cGMP, and matching controls,
but not for ODQ treatments. Removing skin did not delay development.
Cell culture studies
Myotomal muscles were removed from stage 21–23 embryos and were
dissociated (Peng et al., 1991). Cells were cultured in 0.4 cm2 wells (NUNC
Lab-Tek #178599; cells from 0.7–1 embryo per well), which were mounted on
glass coverslips with Sylgard (Dow Corning) and coated with a basement
membrane extract (E.C.L., Upstate) as described (Schwarte and Godfrey, 2004).
Cultures were used for experiments after 1–3 days, when the cells had attached
and spread. Cultures were pretreated with inhibitors for 2 h prior to adding
6–12 ng/ml agrin (half-maximal dose=3.5–5 ng/ml) with or without inhibitors
for 14 h. After 16–18 h at 22 °C, cells were labeled 1 h with Alexa 594-α-
bungarotoxin (1.5 μg/ml), rinsed twice with culture medium and fixed 10 min in
95% ethanol at −20 °C. Cultures were mounted in a glycerol-based mounting
medium containing n-propyl gallate to retard fading of fluorescence (Valnes and
Brandtzaeg, 1985). Aggregates of AChRs (≥1 μm) were counted in each of 20
cells per well in duplicate wells for each condition.
Results
Inhibitors of guanylate cyclase and cGMP-dependent protein
kinase reduce endogenous AChR aggregation at the embryonic
neuromuscular junction, but a cyclic GMP analog greatly
increases AChR aggregate area in vivo
To determine whether the activities of guanylate cyclase
(GC) and cGMP-dependent protein kinase (PKG) are required
Table 1
A cyclic GMP analog increases AChR aggregation and inhibitors of guanylate
cyclase and cGMP-dependent protein kinase reduce endogenous AChR
aggregation at the embryonic neuromuscular junction
Experiment
no.
Treatment AChR
aggregate area
(% ±SEM)
Area ratio
experimental:
control
P vs.
control
1 Control (unskinned) 0.18±0.07 – –
8-Br-cGMP (100 μM) 0.74±0.10 4.0 0.001
2 Control (skinned) 0.34±0.06 – –
8-Br-cGMP (100 μM) 0.987±0.20 2.9 0.004
3 Control (unskinned) 1.36±0.21 – –
ODQ (50 μM) 0.21±0.06 0.15 5×10−5
4 Control (skinned) 0.96±0.21 – –
Rp-8-pCPT-cGMPs
(0.5 mM)
0.48±0.08 0.50 0.05
In Experiments 2 and 4, the skin overlying trunk myotomes was removed by
suction at stage 24. Embryos were exposed to 8-Br-cGMP or inhibitor in 0.1×
MBS (unskinned) or 1× MBS (skinned) from stage 24 until stage 31, when they
were fixed for labeling of AChRs with α-bungarotoxin and subsequent confocal
microscopy. Each type of experiment was performed 2–4 times.
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exposed developing myotomal muscles to inhibitors during the
period when muscles become innervated by motor axons
(stages 24–31). Confocal images were centered on the almost
continuous line of AChR aggregates found on the ends of
muscle cells at the intermyotomal septa, where NMJs form (Fig.
1A). The GC inhibitor ODQ and the PKG inhibitor Rp-8-pCPT-
cGMPS reduced endogenous AChR aggregate area at neuro-
muscular synapses by 85% and 50% on average, respectively
(Figs. 1B, C; Table 1). In contrast, a cell-permeable cGMP
analog, 8-bromo-cGMP, increased AChR aggregate area (Fig.
1D; Table 1) to levels 3–4 times those in untreated control
embryo muscles (e.g., Fig. 1A; Table 1). Despite the changes in
AChR aggregate area, embryos treated with these agents
appeared to develop normally, including the formation of
myotomal muscles. However, treatment with ODQ, but not with
Rp-8 or 8-Br-cGMP, delayed development from stage 24 to
stage 31 by 1–3 h.
To determine whether inhibitors of GC and PKG acted on
muscle cells in a cell-autonomousmanner, we cultured embryonic
myotomal muscle cells that had not yet been innervated.Fig. 1. Inhibitors of GC and PKG reduce endogenous AChR aggregation at the
embryonic neuromuscular junction, and a cyclic GMP analog greatly increases
AChR aggregate area compared to untreated control embryos (A). Embryos
were exposed to the GC inhibitor ODQ (50 μM, B), the PKG inhibitor Rp-8-
pCPT-cGMPS (0.5 mM, C), or the cGMP analog 8-Br-cGMP (100 μM, D)
during the period of neuromuscular junction formation (stages 24–31). In the
experiments shown here, skin was removed from myotomes of embryos treated
with Rp-8-pCPT-cGMPS and 8-Br-cGMP and their respective controls, but not
from embryos treated with ODQ or corresponding controls (A). AChR
aggregates were labeled and imaged by confocal microscopy, and area of
aggregates was quantified (Table 1) with Metamorph image analysis software as
described in Materials and methods. Images shown are maximum projections of
stacks of 4 images taken at 1 μm intervals. In the image stacks projected in this
figure, AChR aggregate area was inhibited 86% by ODQ (B) and 65% by Rp-8-
pCPT-cGMPS (C), and increased 460% by 8-Br-cGMP (D), compared to the
respective untreated controls (e.g., A).Treatment of these cells with the GC inhibitors ODQ (Fig. 2C)
or the PKG inhibitors Rp-8-pCPT-cGMPS (Fig. 2D) or KT5823
(not shown) reduced agrin-induced AChR aggregation (Fig. 2B)
up to 100% (Table 2). Application of inhibitors at the IC50 or Ki
values for themammalian enzymes (* in Table 2; Butt et al., 1994;
Schrammel et al., 1996; Kase et al., 1987) reduced AChR
aggregation in Xenopus embryo muscle cells by 44–70% on
average, suggesting that the effects were specifically due toFig. 2. Inhibitors of GC and PKG block agrin-induced AChR aggregation on
cultured Xenopus embryo myotomal muscle cells. Cells were pretreated with
inhibitors 2.5 h before 17 h incubation with 7 ng/ml agrin (half-maximal dose,
4.4 ng/ml) with or without inhibitors. AChR aggregates (white) were then
labeled with fluorescent α-bungarotoxin, cells were fixed, mounted, and
aggregates counted as described in Materials and methods. In the experiment
from which these images were taken, the average inhibition of agrin-induced
AChR aggregation was 99% with ODQ (2 μM), 75% with KT5823 (1 μM; data
not shown), and 75% with Rp-8-pCPT-cGMPS (0.5 μM). The number of
aggregates per cell in the images shown was 1.8 in untreated control cells (A),
3.4 after agrin treatment (B), 2.5 after agrin plus ODQ (66% inhibition, C), and
0.2 after agrin plus Rp-8-pCPT-cGMPS (88% inhibition, D).
Table 2
Inhibitors of guanylate cyclase (GC) and cGMP-dependent protein kinase
(PKG) block agrin-induced AChR aggregation in cultured embryonic muscle
cells
Inhibitor Concentration Inhibition of agrin-induced AChR
aggregation
Average (%) Range (%) Experiments
ODQ (GC) 20 nM* 44 30–56 5
200 nM 52 8–96 6
2 μM 64 49–100 6
50 μM 100 100–100 2
KT5823 (PKG) 200–250 nM* 64 53–84 5
1 μM 87 67–100 4
Rp-8-pCPT-cGMPs
(PKG)
500 nM* 70 34–100 5
5 μM 60 29–100 7
100 μM 96 92–100 2
Embryonic myotomal muscle cells were cultured 1–3 days as described
in Materials and methods. Cultures were pretreated with inhibitor for 2 h prior
to adding 6–12 ng/ml agrin (half-maximal dose=3.5–5 ng/ml) with inhibitor
for 14 h. After 16–18 h at 22 °C, cells were labeled with Alexa 594-α-
bungarotoxin, fixed, and mounted as described in Materials and methods.
Aggregates of AChRs (≥1 μm) were counted in each of 20 cells per well in
duplicate wells for each condition. Values shown are averages and ranges of
percent inhibition of agrin-induced AChR aggregates/cell in several different
experiments. Asterisks indicate published IC50 or Ki values for each inhibitor.
Table 3
Overexpression of guanylate cyclase increases and a dominant negative form
inhibits AChR aggregation at the embryonic neuromuscular junction
Experiment
no.
RNA injected
(ng/embryo)
AChR aggregate
area (% ±SEM)
Area ratio
GC/control
P vs.
control
1 GFP (1) 1.11±0.26 – –
GC α+β (6) 2.34±0.16 2.1 0.003
GC α (3) 1.20±0.26 1.08 N.S.
GC β (3) 1.08±0.50 0.97 N.S.
2 GFP (1) 1.01±0.14 – –
GC α-D529A (8) 0.51±0.14 0.51 0.028
RNA encoding rat guanylate cyclase (GC) α and/or β subunits, or a dominant
negative mutant form of GC α (D529A), was injected into fertilized Xenopus
embryos at the one-cell stage, and embryos were fixed at stage 31 and analyzed
as described in Materials and methods. All embryos including controls were
injected with 1 ng of GFP RNA as a marker for successful injection.
Overexpression of GC α+β, but not α or β alone, increased AChR aggregate
area at the embryonic neuromuscular junction in four different experiments to
1.8–2.2-fold control values (injection with GFP RNA). Expression of dominant
negative GC α inhibited endogenous AChR aggregation by 49–65% in three
separate experiments. N.S.=not significant (P values of 0.4 and 0.5).
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activity of bothGC and PKG inmuscle cells is necessary for agrin
signaling leading to AChR aggregation.Fig. 3. Overexpression of guanylate cyclase (GC) increases AChR aggregation
in embryonic muscles, but a dominant negative GC inhibits endogenous
aggregation at NMJs. Embryos were injected with RNA encoding GFP (A), GC
α and β subunits (B), GC α only (C), or a dominant negative GC-α construct
(D) encoding an inactive point mutant. GC α+β increased AChR aggregation
2–3-fold, GC α alone did not affect aggregation, but the dominant negative GC
α reduced aggregate area by about 50%. Quantitative data from the experiments
shown here are found in Table 3 (Experiment 1 for panels A–C; Experiment 2
for panel D). Dashed lines in panel C indicate boundaries of muscle fibers. Scale
bar, 20 μm.Overexpression of GC or PKG increases AChR aggregation
and a dominant negative form of GC reduces AChR aggregate
area at the embryonic NMJ
To further assess the role of GC and PKG in postsynaptic
differentiation of the embryonic NMJ, we overexpressed these
enzymes by injecting RNA encoding each enzyme into one-cell
stage embryos. Injection of RNA encoding both α and β
subunits of GC increased AChR aggregate area by 100% over
control embryos (Fig. 3A), but no increase was seen if RNA
encoding only one of these GC subunits was injected (Figs. 3B,
C; Table 3). In contrast, injection of RNA encoding a dominant
negative form of the GC α subunit (D529A; Yuen et al., 1994)
resulted in a 50% decrease in endogenous AChR aggregation
(Fig. 3D; Table 3). When RNA encoding PKGIα was injected,
AChR aggregate area increased by 60–170% (Table 4), similar
to the effect of GC overexpression. Injection of RNA encoding
the fusion protein PKG-GFP, a constitutively active form of
PKG (Browning et al., 2001), resulted in a larger increase in
AChR aggregate area than injection of PKGIα RNA (Table 4).
These results complement our findings with inhibitors and 8-Table 4
Overexpression of cGMP-dependent protein kinase increases AChR aggregation
at the embryonic neuromuscular junction
RNA injected
(ng)
AChR aggregate
area (% ±SEM)
Area ratio
PKG/control
P vs.
control
GFP (1) 0.416+0.11 – –
PKG1α (8) 0.667+0.06 1.63 0.035
PKG-GFP (8) 1.02+0.13 2.45 0.004
RNA encoding human PKG1α, or a constitutively active mutant form of
PKG1α (PKG-GFP), was injected into fertilized Xenopus embryos at the one-
cell stage, and embryos were fixed at stage 31 and analyzed as described in
Materials and methods. All embryos including controls were also injected with
1 ng of GFP RNA. Overexpression of PKG1α increased AChR aggregate area
at the embryonic neuromuscular junction in four different experiments to 1.6–
2.7-fold control values (injection with GFP RNA) and PKG-GFP increased
endogenous AChR aggregation to 2.5-fold control values in two experiments.
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in agrin-induced signaling leading to AChR aggregation at the
embryonic NMJ.
Discussion
In many cell types, NO stimulates the ‘soluble’ guanylate
cyclase (sGC) isoform to synthesize more cyclic GMP, which in
turn activates cGMP-dependent protein kinase (PKG; Hofmann
et al., 2000). Significantly, all three enzymes in this pathway,
NOS, GC, and PKG, are concentrated in the postsynaptic
apparatus of the mammalian NMJ (Chao et al., 1997; Schoser
and Behrends, 2001), suggesting that the NO-cGMP signaling
pathway plays a role in the formation and/or function of this
synapse. We have previously shown that NOS activity is
necessary for postsynaptic differentiation of embryonic NMJs
and agrin-induced AChR aggregation in cultured muscle cells
(Schwarte and Godfrey, 2004). The findings presented here
indicate that activity of both GC and PKG is also critical for
agrin signaling at the NMJ.
The ability of inhibitors of GC and PKG to block
endogenous AChR aggregation at embryonic NMJs indicates
that the activity of these enzymes is important for postsynaptic
differentiation in vivo. Inhibitors completely blocked agrin-
induced AChR aggregation in cultured embryonic muscle cells
and reduced endogenous aggregation at embryonic NMJs by
50–85%. Incomplete inhibition of postsynaptic AChR aggrega-
tion in embryos could reflect incomplete diffusion or instability
of inhibitors in the embryonic muscles. Another possibility is
that compensatory mechanisms allow limited agrin signaling in
embryonic muscles when GC or PKG is inhibited. Although we
favor the first explanation, compensatory mechanisms could
involve cyclic AMP-dependent protein kinase (PKA), which
has recently been shown to activate the small GTPases Rac1
and Cdc42 (O'Connor and Mercurio, 2001; Chadhi et al., 2005;
Howe et al., 2005). These small GTPases are activated during
agrin signaling and their activation is required for AChR
aggregation (Weston et al., 2000; Luo et al., 2003). The
complete inhibition of agrin-induced AChR aggregation by GC
and PKG inhibitors in cultured embryonic muscle cells
indicates that activity of these enzymes is essential for agrin
signaling in these cells. Our results are also consistent with the
effects of the same inhibitors on agrin activity in cultured chick
embryo myotubes (Jones and Werle, 2004), indicating that the
role of GC and PKG in agrin signaling is phylogenetically
conserved.
Overexpression of GC or PKG in embryos resulted in 60–
170% increases in AChR aggregate area in the innervated
regions of embryonic muscles, similar to the effect of
overexpressing agrin and NOS in embryos (Godfrey et al.,
1999; Schwarte and Godfrey, 2004). In contrast, expression of a
dominant negative mutant form of GC reduced AChR aggregate
area in embryonic muscles by 50%. Finally, treating embryos
with the cGMP analog 8-Br-cGMP increased AChR aggregate
area by 200–300%. Taken together, these results indicate that
cGMP stimulates AChR aggregation at NMJs. Moreover,
results with the dominant negative mutant of GC, like theinhibitor studies, suggest that GC activity is critical to agrin
signaling in embryonic muscles.
Another possible interpretation of the inhibition or increase
of AChR aggregation we observed in embryonic muscles and in
cultured muscle cells is that the changes in aggregation reflect
changes in the number of AChRs on the surface of the muscle
cells. Acetylcholine receptors shuttle between intracellular
membrane compartments and the plasma membrane of skeletal
muscle cells (Fambrough, 1979). Recycling of receptors has
also been observed at the NMJ in vivo (Bruneau et al., 2005;
Bruneau and Akaaboune, 2006). Thus, changes in AChR
aggregation on the surface of muscle cells could reflect changes
in insertion and/or removal of AChRs from the plasma
membrane. However, the number of surface AChRs in cultured
chick embryo myotubes was not significantly changed by
treatment with agrin, 8-Br-cGMP, or the GC inhibitor ODQ in
combination with agrin (Jones and Werle, 2004). Thus, it is
possible but unlikely that the changes in AChR aggregation we
observed with the same agents in cultured frog embryo muscle
cells and embryonic muscles were due to changes in the number
of AChRs on the surface of the muscle cells.
Intracellular signaling molecules can be categorized as
mediators or modulators (Sanes and Lichtman, 1999a).
Mediators are essential molecules required for signaling to
occur. Studies with null mutant mice have established that
postsynaptic AChR aggregation at the NMJ requires agrin, its
receptor MuSK, and rapsyn, which links clustered AChRs to the
cytoskeleton (Sanes and Lichtman, 2001). Modulators are
molecules that enhance or inhibit signaling but are less
essential. Nitric oxide and cyclic GMP are clearly important
for agrin signaling, but are they essential mediators or
modulators? The evidence to date suggests that NO and
cGMP mediate agrin signaling in frog embryos and chick
embryo muscle cells. First, inhibitors of NOS and GC
completely blocked agrin-induced AChR aggregation in cul-
tured muscle cells from both organisms (Jones and Werle, 2000;
Schwarte and Godfrey, 2004; Jones and Werle, 2004; this
report). Second, inhibitors of NOS, GC, and PKG blocked up to
90% of endogenous AChR aggregation at embryonic frog
NMJs (Schwarte and Godfrey, 2004; this report). Third, both
NO donors and a cGMP analog mimicked agrin by aggregating
AChRs in both cultured muscle cells (including those from
mouse) and embryonic muscles, a result not expected if NO and
cGMP are modulators of agrin signaling (Jones and Werle,
2000; Schwarte and Godfrey, 2004; Jones and Werle, 2004; M.
Parasa, R.C. Schwarte and E.W. Godfrey, unpublished results).
Fourth, 8-Br-cGMP does not potentiate agrin signaling at a
saturating dose of agrin, indicating that cGMP acts within the
agrin pathway (Jones and Werle, 2004). Determining the extent
and manner by which NO and cGMP mediate agrin signaling
will require further studies to understand how they are regulated
during this process and to identify their downstream targets.
Which effectors of agrin signaling could be activated by GC
and PKG? Recent findings show that agrin-induced polymer-
ization of actin microfilaments is required for clustering of
AChRs and other associated proteins (Dai et al., 2000). Two
Rho GTPases, Rac and Rho, which control the organization of
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and, when expressed together, sufficient for aggregation of
AChRs in myotubes (Weston et al., 2000, 2003). Agrin activates
both Rac and Rho in myotubes (Weston et al., 2000, 2003), as
well as p21-activated kinase (PAK1), a known target of Rac1
(Luo et al., 2003). These findings suggest that Rac and Rho are
essential components for agrin signaling in muscle cells.
Activity of NOS and PKG may in turn regulate Rac in agrin
signaling. Our preliminary results suggest that agrin-induced
Rac activation in mouse myotubes requires NOS activity (R.C.
Schwarte and E.W. Godfrey, unpublished results). Furthermore,
brief treatment of myotubes with NO donors or 8-bromo-cyclic
GMP induces AChR aggregation and activates Rac (R.C.
Schwarte, M. Parasa, and E.W. Godfrey, unpublished results).
Thus, Rac activation appears to be downstream of NOS (and
possibly GC) activity during agrin signaling.
A potential target of the NO/cGMP pathway is one or more of
the guanine-nucleotide exchange factors (GEFs), which activate
Rho GTPases by stimulating GTP exchange (Hall, 1998; Jaffe
andHall, 2005; Overbeck et al., 1995). Phosphorylation of GEFs
activates Rho GTPases (Aghazadeh et al., 2000; Kiyono et al.,
2000). For example, PKG could phosphorylate a Rac-specific
GEF during agrin signaling. Consistent with this notion, PKG
activates Rac1 indirectly in HEK-293 cells (Hou et al., 2004).
Thus, it will be important to determine whether GEFs are
phosphorylated by PKG during agrin signaling, and if so,
whether the phosphorylated GEFs activate Rac and/or Rho in
response to agrin.
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